farmaecFARMAKOEKONOMIKA. Modern Pharmacoeconomics and PharmacoepidemiologyФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология2070-49092070-4933IRBIS LLC10.17749/2070-4909/farmakoekonomika.2023.192farmaec-863Research ArticleORIGINAL ARTICLESОРИГИНАЛЬНЫЕ ПУБЛИКАЦИИComparative chemomicrobiomic analysis of bacteriocinsСравнительный хемомикробиомный анализ бактериоциновhttps://orcid.org/0000-0002-2659-7998ТоршинИ. Ю.TorshinI. Yu.

Торшин Иван Юрьевич – к.ф-м.н., к.х.н., старший научный сотрудник 

WoS ResearcherID: C-7683-2018; Scopus Author ID: 7003300274

ул. Вавилова, д. 44, корп. 2, Москва 119333

Ivan Yu. Torshin – PhD (Phys. Math.), PhD (Chem.), Senior Researcher

WoS ResearcherID: C-7683-2018; Scopus Author ID: 7003300274

44 corp. 2 Vavilov Str., Moscow 119333

https://orcid.org/0000-0002-7663-710XГромоваО. А.GromovaO. A.

Громова Ольга Алексеевна – д.м.н., профессор, ведущий научный сотрудник

WoS ResearcherID: J-4946-2017; Scopus Author ID: 7003589812

ул. Вавилова, д. 44, корп. 2, Москва 119333

Olga A. Gromova – Dr. Med. Sc., Professor, Leading Researcher

WoS ResearcherID: J-4946-2017; Scopus Author ID: 7003589812

44 corp. 2 Vavilov Str., Moscow 119333

unesco.gromova@gmail.comФедеральный исследовательский центр «Информатика и управление» Российской академии наукРоссияFederal Research Center “Computer Science and Control”, Russian Academy of SciencesRussian Federation202325092023164643656Copyright © Torshin I.Y., Gromova O.A., 20242024Торшин И.Ю., Громова О.А.Torshin I.Y., Gromova O.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacoeconomics.ru/jour/article/view/863

Objective: comprehensive analysis of the spectrum of antibacterial action of bactеriocins.Material and methods. Chemomicrobiome analysis of bacteriocins A/B, C, S, 28b, RS-2020 was performed to assess the minimum inhibitory concentration (MIC) values for 152 strains of pathogenic bacteria and the area under the growth curve (AUC) values for a representative sample of normobiota (38 human commensal bacteria).Results. Compared to other molecules, bacteriocin C was characterized by lower MIC constants for a wide range of pathogenic bacterial strains. Thus, it more effectively inhibited strains of pathogens of bacterial pneumonia (H. influenzae, S. mutans, S. pneumoniae, S. pyogenes), nosocomial infections (K. pneumoniae, P. aeruginosa, S. aureus, S. epidermidis, S. pneumoniae), skin diseases (M. audouinii, T. mentagrophytes, etc.), urinary tract infections (E. cloacae, P. mirabilis and P. vulgaris), Fusobacterium necrophorum and Candida fungi. At the same time, bacteriocin C to a lesser extent than the reference molecules inhibited the growth of the normophysiological microbiota of the Bacteroides, Enterococcus genera, non-pathogenic Escherichia, yeast S. cerevisiae and others. By stimulating butyrate (butyric anion) producing microorganisms, bacteriocin C can exhibit prebiotic properties.Conclusion. The main structural features of the bacteriocin C molecule associated with the antibacterial effect on pathogenic microbiota were identified and described.

Цель

Цель: комплексный анализ спектра антибактериального действия бактриоцинов.

Материал и методы

Материал и методы. Проведен хемомикробиомный анализ бактериоцинов A/B, C, S, 28b, RS-2020 для оценки значений минимальных ингибирующих концентраций (англ. minimum inhibitory concentration, MIC) для 152 штаммов болезнетворных бактерий и значений площади под кривой роста (англ. area under curve AUC) для репрезентативной выборки нормобиоты (38 бактерий – комменсалов человека).

Результаты

Результаты. По сравнению с другими молекулами бактериоцин С характеризовался меньшими значениями констант MIC для широкого круга штаммов патогенных бактерий. Так, он более эффективно ингибировал штаммы возбудителей бактериальной пневмонии (H. influenzae, S. mutans, S. pneumoniae, S. pyogenes), внутрибольничных инфекций (K. pneumoniae, P. aeruginosa, S. aureus, S. epidermidis, S. pneumoniae), заболеваний кожи (M. audouinii, T. mentagrophytes и др.), инфекций мочевыводящий путей (E. cloacae, протеи P. mirabilis и P. vulgaris), Fusobacterium necrophorum и грибов Candida. В то же время бактериоцин С в меньшей степени, чем молекулы сравнения, тормозил рост нормофизиологической микробиоты родов Bacteroides, Enterococcus, непатогенных Escherichia, дрожжей S. cerevisiae и др. Стимулируя микроорганизмы – продуценты бутирата (анион масляной кислоты), бактериоцин С может проявлять пребиотические свойства.

Заключение

Заключение. Выявлены и описаны основные структурные признаки молекулы бактериоцина С, связанные с антибактериальным воздействием на патогенную микробиоту.

Бактериальные патогенымикробиом человекаплощадь под кривой ростафармакоинформационные технологиихемоинформатикаанализ хемографовBacterial pathogenshuman microbiomearea under the growth curveAUCpharmacoinformaticschemoinformaticschemograph analysisРабота выполнена при поддержке гранта Российского научного фонда (проект № 23-21-00154 «Разработка методов прогноза свойств фармакологических препаратов по их молекулярной структуре с помощью теории топологического анализа хемографов»).The work was supported by a grant from the Russian Science Foundation (project no. 23-21-00154 “Development of methods for predicting the properties of pharmacological preparations by their molecular structure using the theory of topological analysis of chemographs”).ReferencesMarx J., Hockberger R., Walls R. Rosen's emergency medicine: concepts and clinical practice. 7th ed. Chapter 30. Philadelphia, Pennsylvania: Mosby; 2010.Marx J., Hockberger R., Walls R. Rosen's emergency medicine: concepts and clinical practice. 7th ed. Chapter 30. Philadelphia, Pennsylvania: Mosby; 2010.Bisno A.L. Acute pharyngitis. N Engl J Med. 2001; 344 (3): 205–11. https://doi.org/10.1056/NEJM200101183440308.Bisno A.L. Acute pharyngitis. N Engl J Med. 2001; 344 (3): 205–11. https://doi.org/10.1056/NEJM200101183440308.Baltimore R.S. Re-evaluation of antibiotic treatment of streptococcal pharyngitis. Curr Opin Pediatr. 2010; 22 (1): 77–82. https://doi.org/10.1097/MOP.0b013e32833502e7.Baltimore R.S. Re-evaluation of antibiotic treatment of streptococcal pharyngitis. Curr Opin Pediatr. 2010; 22 (1): 77–82. https://doi.org/10.1097/MOP.0b013e32833502e7.Wang F., Qin L., Pace C.J., et al. Solubilized gramicidin A as potential systemic antibiotics. Chembiochem. 2012; 13 (1): 51–5. https://doi.org/10.1002/cbic.201100671.Wang F., Qin L., Pace C.J., et al. Solubilized gramicidin A as potential systemic antibiotics. Chembiochem. 2012; 13 (1): 51–5. https://doi.org/10.1002/cbic.201100671.Palm J., Fuchs K., Stammer H., et al. Efficacy and safety of a triple active sore throat lozenge in the treatment of patients with acute pharyngitis: Results of a multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial (DoriPha). Int J Clin Pract. 2018; 72 (12): e13272. https://doi.org/10.1111/ijcp.13272.Palm J., Fuchs K., Stammer H., et al. Efficacy and safety of a triple active sore throat lozenge in the treatment of patients with acute pharyngitis: Results of a multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial (DoriPha). Int J Clin Pract. 2018; 72 (12): e13272. https://doi.org/10.1111/ijcp.13272.Lum K., Ingólfsson H.I., Koeppe R.E. II, Andersen O.S. Exchange of gramicidin between lipid bilayers: implications for the mechanism of channel formation. Biophys J. 2017; 113 (8): 1757–67. https://doi.org/10.1016/j.bpj.2017.08.049.Lum K., Ingólfsson H.I., Koeppe R.E. II, Andersen O.S. Exchange of gramicidin between lipid bilayers: implications for the mechanism of channel formation. Biophys J. 2017; 113 (8): 1757–67. https://doi.org/10.1016/j.bpj.2017.08.049.Регистр лекарственных средств России. Грамицидин С (Gramicidinum S). URL: https://www.rlsnet.ru/active-substance/gramicidin-s-1294 (дата обращения 30.03.2023).Register of Medicines of Russia. Gramicidinum S. Available at: https://www.rlsnet.ru/active-substance/gramicidin-s-1294 (in Russ.) (accessed 30.03.2023).Schripsema J., de Rudder K.E., van Vliet T.B., et al. Bacteriocin small of Rhizobium leguminosarum belongs to the class of N-acyl-L-homoserine lactone molecules, known as autoinducers and as quorum sensing co-transcription factors. J Bacteriol. 1996;178 (2):366–71. https://doi.org/10.1128/jb.178.2.366-371.1996.Schripsema J., de Rudder K.E., van Vliet T.B., et al. Bacteriocin small of Rhizobium leguminosarum belongs to the class of N-acyl-L-homoserine lactone molecules, known as autoinducers and as quorum sensing co-transcription factors. J Bacteriol. 1996;178 (2):366–71. https://doi.org/10.1128/jb.178.2.366-371.1996.Enfedaque J., Ferrer S., Guasch J.F., et al. Bacteriocin 28b from Serratia marcescens N28b: identification of Escherichia coli surface components involved in bacteriocin binding and translocation. Can J Microbiol. 1996; 42 (1): 19–26. https://doi.org/10.1139/m96-004.Enfedaque J., Ferrer S., Guasch J.F., et al. Bacteriocin 28b from Serratia marcescens N28b: identification of Escherichia coli surface components involved in bacteriocin binding and translocation. Can J Microbiol. 1996; 42 (1): 19–26. https://doi.org/10.1139/m96-004.Торшин И.Ю., Громова О.А., Захарова И.Н., Максимов В.А. Хемомикробиомный анализ Лактитола. Экспериментальная и клиническая гастроэнтерология. 2019; 164 (4): 111–21. https://doi.org/10.31146/1682-8658-ecg-164-4-111-121.Torshin I.Yu., Gromova O.A., Zakcharova I.N., Maximov V.A. Hemomikrobiomny lactitol analysis. Experimental and Clinical Gastroenterology. 2019; 164 (4): 111–21 (in Russ.). https://doi.org/10.31146/1682-8658-ecg-164-4-111-121.Торшин И.Ю., Галустян А.Н., Иванова М.И. и др. Хемомикробиомный анализ синергизма D-маннозы и D-фруктозы в сравнении с другими метабиотиками. Эффективная фармакотерапия. 2020; 16 (20): 22–31.Torshin I.Yu., Galustyan A.N., Ivanova M.I., et al. Chemomicrobiome analysis of synergism of D-mannose and D-fructose in comparison with other metabiotics. Effective Pharmacotherapy. 2020; 16 (20): 22–31 (in Russ.).Громова О.А., Торшин И.Ю., Наумов А.В., Максимов В.А. Хемомикробиомный анализ глюкозамина сульфата, пребиотиков и нестероидных противовоспалительных препаратов. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2020; 13 (3): 270–82. https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.049.Gromova O.A., Torshin I.Yu., Naumov A.V., Maksimov V.A. Chemomicrobiomic analysis of glucosamine sulfate, prebiotics and non-steroidal anti-inflammatory drugs. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020; 13 (3): 270–82 (in Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.049.Torshin I.Yu., Rudakov K.V. On metric spaces arising during formalization of problems of recognition and classification. Part 2: Density properties. Pattern Recognit Image Anal. 2016; 26 (3): 483–96. https://doi.org/10.1134/S1054661816030202.Torshin I.Yu., Rudakov K.V. On metric spaces arising during formalization of problems of recognition and classification. Part 2: Density properties. Pattern Recognit Image Anal. 2016; 26 (3): 483–96. https://doi.org/10.1134/S1054661816030202.Torshin I.Yu, Rudakov K.V. On the theoretical basis of metric analysis of poorly formalized problems of recognition and classification. Pattern Recognit Image Anal. 2015; 25 (4): 577–87. https://doi.org/10.1134/S1054661815040252.Torshin I.Yu, Rudakov K.V. On the theoretical basis of metric analysis of poorly formalized problems of recognition and classification. Pattern Recognit Image Anal. 2015; 25 (4): 577–87. https://doi.org/10.1134/S1054661815040252.Torshin I.Yu, Rudakov K.V. On the procedures of generation of numerical features over the splits of a set of objects and the problem of prediction of numeric target variables. Pattern Recognit Image Anal. 2019; 29 (4): 654–67. https://doi.org/10.1134/S1054661819040175 .Torshin I.Yu, Rudakov K.V. On the procedures of generation of numerical features over the splits of a set of objects and the problem of prediction of numeric target variables. Pattern Recognit Image Anal. 2019; 29 (4): 654–67. https://doi.org/10.1134/S1054661819040175 .The Human Microbiome Project Consortium. A framework for human microbiome research. Nature. 2012; 486 (7402): 215–21. https://doi.org/10.1038/nature11209.The Human Microbiome Project Consortium. A framework for human microbiome research. Nature. 2012; 486 (7402): 215–21. https://doi.org/10.1038/nature11209.The Integrative HMP (iHMP) Research Network Consortium. The Integrative Human Microbiome Project: dynamic analysis of microbiome-host omics profiles during periods of human health and disease. Cell Host Microbe. 2014; 16 (3): 276–89. https://doi.org/10.1016/j.chom.2014.08.014.The Integrative HMP (iHMP) Research Network Consortium. The Integrative Human Microbiome Project: dynamic analysis of microbiome-host omics profiles during periods of human health and disease. Cell Host Microbe. 2014; 16 (3): 276–89. https://doi.org/10.1016/j.chom.2014.08.014.Kim S., Chen J., Cheng T., et al. PubChem 2019 update: improved access to chemical data. Nucleic Acids Res. 2019; 47 (D1): D1102–9. https://doi.org/10.1093/nar/gky1033.Kim S., Chen J., Cheng T., et al. PubChem 2019 update: improved access to chemical data. Nucleic Acids Res. 2019; 47 (D1): D1102–9. https://doi.org/10.1093/nar/gky1033.Maier L., Pruteanu M., Kuhn M., et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018; 555 (7698): 623–8. https://doi.org/10.1038/nature25979.Maier L., Pruteanu M., Kuhn M., et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018; 555 (7698): 623–8. https://doi.org/10.1038/nature25979.Saavedra J.M. Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities. Cell Mol Neurobiol. 2005; 25 (3–4): 485–512. https://doi.org/10.1007/s10571-005-4011-5.Saavedra J.M. Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities. Cell Mol Neurobiol. 2005; 25 (3–4): 485–512. https://doi.org/10.1007/s10571-005-4011-5.

The authors declare that there are no conflicts of interest present.